Stocktoria
Citius Pharmaceuticals, Inc. CTXR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-08-03
Citius Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $90,000 | $90,000 |
| R&D expense | $9.2M | $11.9M | $14.8M | $17.7M | $12.2M |
| Operating income | -$38.5M | -$42.0M | -$36.7M | -$33.3M | -$23.5M |
| Interest expense | — | — | — | — | $10,839 |
| Income tax | $1.1M | $576,000 | $576,000 | $576,000 | $1,233 |
| Net income | — | — | -$32.5M | -$33.6M | -$23.1M |
| EPS (diluted) | $-3.38 | $-5.97 | $-5.57 | $-0.23 | $-0.23 |
| Operating cash flow | -$26.6M | -$28.2M | -$29.1M | -$28.4M | -$24.3M |
| Free cash flow | — | — | — | — | -$24.3M |
| Cash & equivalents | $4.3M | $3.3M | $26.5M | $41.7M | $70.1M |
| Inventory | $22.3M | $8.3M | — | — | — |
| Total assets | $130.9M | $116.7M | $103.6M | $114.0M | $142.4M |
| Total liabilities | $53.4M | $42.5M | $12.2M | $10.6M | $9.6M |
| Shareholders' equity | $77.5M | $74.1M | $91.4M | $103.4M | $132.8M |
Source: SEC EDGAR filings · CIK 0001506251 · as of 2025-09-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.